Medicus Pharma (NASDAQ:MDCX - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.19), Zacks reports.
Medicus Pharma Stock Up 5.9%
Shares of NASDAQ:MDCX traded up $0.27 during midday trading on Monday, hitting $4.86. 224,879 shares of the stock were exchanged, compared to its average volume of 54,763. Medicus Pharma has a twelve month low of $1.80 and a twelve month high of $6.01. The firm has a 50 day simple moving average of $3.65.
Analysts Set New Price Targets
A number of research firms have commented on MDCX. D. Boral Capital raised their target price on Medicus Pharma from $14.00 to $27.00 and gave the company a "buy" rating in a report on Monday. D Boral Capital raised Medicus Pharma to a "strong-buy" rating in a research note on Monday, April 14th. Finally, Maxim Group lifted their price target on Medicus Pharma from $10.00 to $20.00 and gave the stock a "buy" rating in a research note on Thursday.
Get Our Latest Research Report on MDCX
Medicus Pharma Company Profile
(
Get Free Report)
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medicus Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicus Pharma wasn't on the list.
While Medicus Pharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
